JPRN-UMIN000002398
Completed
Phase 2
Phase II study of intensive chemotherapy in treating pediatric patients with newly diagnosed cranial nongerminomaous germ cell tumor - Intensive chemotherapy in treating pediatric patients with cranial nongerminomaous germ cell tumor
Japanese Pediatric Brain Tumor Consortiun0 sites20 target enrollmentAugust 28, 2009
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Japanese Pediatric Brain Tumor Consortiun
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Has double cancer. Has cardiac disease for which treatment is necessary.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of Chemotherapy for Advanced or Recurrent ThymomaThymoma (excluding thymic carcinoma)JPRN-C000000350Japanese Association for Research on the Thymus50
Recruiting
Phase 2
Phase II study of elental for chemotherapy induced mucositis oral and nutritional disturbanceJPRN-UMIN000009298Aizawa Hospital30
Completed
Not Applicable
A phase II study of preoperative chemotherapy cosisting docetaxel, oxaliplatin and S-1 for the clinical Stage III gastric cancerGastric cancerJPRN-UMIN000017652Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine50
Active, not recruiting
Phase 1
A PHASE II EVALUATION OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR INTESTINAL AND OTHER DEFINED HISTOLOGICAL SUBTYPES OF AGGRESSIVE T-CELL LYMPHOMA - ATCL TrialDefined histological subtypes of aggressive T-Cell Lymphoma: - Intestinal T-cell / Enteropathy-type T-Cell lymphoma (ETL) - Peripheral T-cell lymphoma NOS - Hepatosplenic T-cell lymphoma - ALK negative Anaplastic T-Cell Lymphoma - Extranodal NK/T-cell lymphomaMedDRA version: 20.0 Level: LLT Classification code 10034624 Term: Peripheral T-cell lymphoma unspecified NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10066957 Term: Hepatosplenic T-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10022703 Term: Intestinal T-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10065855 Term: Extranodal NK/T-cell lymphoma, nasal type System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2005-003906-27-GBniversity College London22
Completed
Phase 2
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22